falsefalse

Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma - Episode 16

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

, , , ,

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
    EP. 2: Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
    EP. 3: Defining Frailty in Multiple Myeloma for Optimal Treatment
    EP. 4: Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
    EP. 5: Relapse in Multiple Myeloma: Biochemical and Chemical
    EP. 6: Data Updates in the Treatment of Relapsed Multiple Myeloma
    EP. 7: Strategies for Treatment of Multiple Myeloma at Late Relapse
    EP. 8: Quadruplet Combination Therapies in Relapsed Multiple Myeloma
    EP. 9: Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
    EP. 10: CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
    EP. 11: BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
    EP. 12: Retreatment with a BCMA-Targeting Bispecific for R/R MM
    EP. 13: Data Updates on Immunotherapy Combinations in Multiple Myeloma
    EP. 14: Targets in Multiple Myeloma: GPRC5D
    EP. 15: Targets in Multiple Myeloma: FcRH5
    Now Viewing
    EP. 16: Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma
    EP. 17: Preventing Infection in Patients with Multiple Myeloma During Treatment
    EP. 18: Does Belantamab Have a Place in Multiple Myeloma Treatment?
    EP. 19: Unmet Needs and Future Perspectives in Multiple Myeloma Care

    Related Content:

    Expert Perspectives on the Evolving Treatment Landscape of Multiple MyelomaOncLive Peer Exchange® Multiple Myeloma
    Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma
    Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma
    Dr Dholaria on the Rationale for Investigating P-BCMA-ALLO1 in R/R Myeloma
    x